BRTX BioRestorative: יחס חוב כולל להון עצמי

The BioRestorative Therapies (BRTX) ecosystem relies on the ThermoCell cellular platform to combat excess weight and metabolic disorders. BioRestorative Therapies creates unique bone marrow-derived drugs to treat back pain, leveraging patent protection and stringent regulatory requirements. Steady development is ensured by a strong team of researchers with equity options. The price action on this chart shows that the debt-to-equity ratio is 0.01.

For BioRestorative Therapies (BRTX), which focuses on early-stage cellular research with a minimal environmental footprint, the change in the total debt-to-equity ratio reflects the degree of financial leverage. This ratio compares total liabilities to net assets, allowing investors to assess the company's reliance on borrowed funds and the risks associated with debt service in the absence of stable revenue.